Further investigation of the mechanisms leading to HERV-K10 expression could pave the way for novel therapeutic strategies for chronic HBV, potentially reducing inflammation and the risk of secondary complications such as autoimmune diseases in affected patients. This evidence concerns the gene KRT10 and autoimmune disease.